# Salveen Richter (Goldman Sachs): Analyst Track Record and Price‑Target Accuracy > How often Salveen Richter’s price targets were reached, how fast, and what the stocks did after each call: a 7‑year backtest of 1,258 ratings, compared with the average Wall Street analyst. Source: https://www.exent.ai/analysts/salveen-richter · Reviewed by David, Senior Analyst, Exent · Published Oct 26, 2026 · Updated Nov 11, 2026 **What changed since Nov 2, 2026:** rank #998 → #884 · 7 new ratings (TLV-TEVA, AMGN, SMMT) · rating 4.6★ → 4.7★ · price‑target hit rate 42.4% → 44.3% ## Key takeaways - Salveen Richter ranks #883 of 1,181 analysts in Exent’s scoring (4.7★). - 44.3% of price targets were reached over 7 years, versus 53.1% for the average analyst. - Median time to reach a target: 92 days; 46.1% of calls were up 12 months later. - Most‑covered stocks: MRNA, BIIB, REGN, VRTX. - Free on Exent: Salveen Richter’s full record, with ratings 3 days after publication. ## Salveen Richter’s track record at a glance Salveen Richter of [Goldman Sachs](https://www.exent.ai/firms/goldman-sachs) ranks **#883** of the 1,181 analysts Exent scores, with a 4.7★ rating and a focus on [healthcare](https://www.exent.ai/analysts/sectors/healthcare). Over a 7‑year lookback, **44.3%** of Salveen’s price targets were reached, 8.8 points below the 53.1% average across all analysts. | Metric | Salveen Richter | All analysts | | --- | --- | --- | | Price‑target hit rate | 44.3% | 53.1% | | Median days to hit target | 92 days | 93 days | | Calls up after 12 months | 46.1% | 64.4% | | Median 12‑month return of calls | −6.6% | +13.5% | | Hit rate, last 2 years | 49.2% | — | | Average worst drop after a call | −28.4% | — | | Ratings in the sample | 1,258 | — | | Stocks covered | 59 | — | The full records of Exent’s top 50 analysts and the top 50 of each sector, and the stocks where several of them agree right now, are members‑only in [Exent Gems](https://www.exent.ai/radar). ## How fast price targets were reached | Time to reach the target | Salveen Richter | | --- | --- | | Under 30 days | 28.5% | | 30–90 days | 21.1% | | 90–180 days | 22.7% | | Over 180 days | 27.6% | Share of the targets that were reached, by how long they took. Targets are usually set for 12 months. ## Stocks Salveen Richter covers most | Stock | Ratings in the sample | | --- | --- | | [MRNA](https://www.exent.ai/stocks/mrna) | 34 | | [BIIB](https://www.exent.ai/stocks/biib) | 33 | | [REGN](https://www.exent.ai/stocks/regn) | 32 | | [VRTX](https://www.exent.ai/stocks/vrtx) | 28 | | [ALNY](https://www.exent.ai/stocks/alny) | 27 | | [AMGN](https://www.exent.ai/stocks/amgn) | 21 | | QURE | 20 | | [GILD](https://www.exent.ai/stocks/gild) | 17 | In the past year Salveen’s ratings were 61% Buy, 36% Hold and 3% Sell. ## Exent’s top 50 analysts Across 983,543 ratings, the average Wall Street analyst’s price target was reached 53.1% of the time: close to a coin flip. The spread between analysts is wide, and 14.3% of the 965 analysts with a measurable record reached 70% or more (Exent data, Nov 9, 2026). Exent Gems is built on the top 50 of Exent’s ranking. Over the last two years, some of them reached 90% or more of their price targets. Who they are, which stocks they are calling now and how often they have been right is for members. [Unlock the top 50 analysts](https://www.exent.ai/radar) ## Salveen Richter’s latest ratings | Date | Stock | Action | Rating | Price target | | --- | --- | --- | --- | --- | | Nov 10, 2026 | Members only | Members only | Members only | Members only | | Nov 9, 2026 | Members only | Members only | Members only | Members only | | Nov 4, 2026 | TLV-TEVA | Reiterated: Buy | Buy | $17346.44 | | Nov 4, 2026 | [AMGN](https://www.exent.ai/stocks/amgn) | Maintained: Buy | Buy | $536.00 | | Nov 4, 2026 | SMMT | Reiterated: Buy | Buy | $43.00 | | Nov 4, 2026 | RARE | Maintained: Hold | Hold | $17.00 | | Nov 3, 2026 | [VRTX](https://www.exent.ai/stocks/vrtx) | Rated: Buy | Buy | $725.00 | | Oct 30, 2026 | [ALNY](https://www.exent.ai/stocks/alny) | Reiterated: Buy | Buy | $320.00 | | Oct 29, 2026 | [AMRX](https://www.exent.ai/stocks/amrx) | Reiterated: Buy | Buy | $24.00 | | Oct 29, 2026 | [GILD](https://www.exent.ai/stocks/gild) | Reiterated: Hold | Hold | $155.00 | | Oct 27, 2026 | [MRNA](https://www.exent.ai/stocks/mrna) | Maintained: Hold | Hold | $137.00 | | Oct 26, 2026 | [VRTX](https://www.exent.ai/stocks/vrtx) | Maintained: Buy | Buy | $654.00 | Salveen published 2 ratings in the last 3 days, the latest on Nov 10, 2026. Salveen’s ratings are free on Exent 3 days after publication. [Exent Gems](https://www.exent.ai/radar) has them the same day, with the calls of the top‑ranked analysts and the stocks where several of them agree. ## More analysts to compare Also at [Goldman Sachs](https://www.exent.ai/firms/goldman-sachs): [Matthew Dellatorre](https://www.exent.ai/analysts/matthew-dellatorre) · [Michele Della Vigna](https://www.exent.ai/analysts/michele-della-vigna) · [Duffy Fischer](https://www.exent.ai/analysts/duffy-fischer) · [Neil Mehta](https://www.exent.ai/analysts/neil-mehta) · [Alexander Duval](https://www.exent.ai/analysts/alexander-duval) · [Eric Sheridan](https://www.exent.ai/analysts/eric-sheridan) Also covering [healthcare](https://www.exent.ai/analysts/sectors/healthcare): [Luke Sergott](https://www.exent.ai/analysts/luke-sergott) · [Joseph Catanzaro](https://www.exent.ai/analysts/joseph-catanzaro) · [Oliver McCammon](https://www.exent.ai/analysts/oliver-mccammon) · [Justin Walsh](https://www.exent.ai/analysts/justin-walsh) · [Bradley Bowers](https://www.exent.ai/analysts/bradley-bowers) · [Cory Jubinville, PhD](https://www.exent.ai/analysts/cory-jubinville,-phd) ## How Exent scores analysts Exent replays every rating with a price target over a 7‑year lookback: was the target reached, how long it took, and what the stock returned 1, 3, 6 and 12 months after the call. The star rating and rank combine success rate, average return and the number of ratings, so a few lucky calls do not make a top analyst. Statistics as of Nov 9, 2026; ranking updated Nov 11, 2026. [How accurate are analyst price targets overall?](https://www.exent.ai/resources/are-analyst-price-targets-accurate) Past performance does not guarantee future results. Historical figures are calculated by Exent from market data and are for education only; they are not investment advice or a recommendation to buy or sell any security. ## Follow the analysts with the best records 1. Exent Gems shows live ratings from the top‑ranked analysts, without the 3‑day delay used on this page. 2. Gems are the stocks where several 4★+ analysts agree: Exent’s shortlist of high‑conviction ideas. 3. Check any idea against your own portfolio: correlation, concentration and crash exposure before you buy. Exent is our product: [Exent Gems](https://www.exent.ai/radar) ## Frequently asked questions ### Is Salveen Richter a good analyst? By Exent’s scoring Salveen Richter ranks #883 of 1,181 with a 4.7★ rating. 44.3% of price targets were reached over a 7-year lookback (all analysts: 53.1%), and 46.1% of calls were up 12 months later. Past accuracy does not guarantee future accuracy. ### What is Salveen Richter’s success rate? In Exent’s 7-year price-target backtest, 44.3% of Salveen Richter’s price targets were reached, with a median of 92 days to reach a target (all analysts: 53.1%). ### Which stocks does Salveen Richter cover? Salveen Richter (Goldman Sachs) covers 59 stocks, mostly in healthcare. The most frequently rated are MRNA, BIIB, REGN, VRTX, ALNY. --- Educational content, not investment advice. Past performance does not guarantee future results.